Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back to main page
NEW:
Evidence
Click below to explore the latest additions to VERI
Click below to explore the latest additions to VERI
Drugs (2)
Evidence (5)
Biomarker (5)
BRAF V600
BRAF V600E
BRAF fusion
BRAF rearrangement
No biomarker
Cancer type (2)
Glioma
Multiple Myeloma
Therapy (3)
ciltacabtagene autoleucel
tovorafenib
trametinib + dabrafenib
BRAF V600E
BRAF V600E
Glioma
Glioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
Novartis Press Release - 3 days
trametinib + dabrafenib
Sensitive: A2 - Guideline
Novartis Press Release - 3 days
BRAF V600
BRAF V600
Glioma
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
BRAF fusion
BRAF fusion
Glioma
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
BRAF rearrangement
BRAF rearrangement
Glioma
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
tovorafenib
Sensitive: A1 - Approval
BioSpace - 4 days
No biomarker
No biomarker
Multiple Myeloma
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 5 days
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 5 days
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
